PORTFOLIO AND THERAPEUTIC FOCUS

We launch new companies to develop lead drugs for therapeutic areas in need of better treatments.

Paragon launches biopharmaceutical companies that embody our core value of patient-centric, biomedical innovation.

LAUNCHED BY PARAGON

Castle Creek Pharma

Castle Creek Pharma employs a unique strategy in selective asset identification and capital efficient development that is driving the company to become one of the industry’s most prolific developers of innovative and high potential late stage therapies for rare genetic dermatology conditions. For more information, please visit www.castlecreekpharma.com.

Paragon-BioSci-Decade-Logo

INCUBATING

Decade Pharmaceuticals

Decade is a research and development company focused on novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes and quality of life.

Emalex Biosciences

Emalex is committed to developing effective treatments for the Central Nervous System (CNS). Emalex’s focus is on making lives easier for the courageous people living with CNS disorders. For more information, please visit www.emalexbiosciences.com.

Harmony Biosciences

Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on therapies for sleep and cognitive disorders, Harmony’s goal is to push the boundaries of what science can do to improve the lives of patients. For more information, please visit www.harmonybiosciences.com.

Immunogenix_Logo1

INCUBATING

Immunogenix

Developing the latest therapies for those living with serious immunology conditions.

Qlarity Imaging

Qlarity Imaging improves patient care by building AI-driven products that provide clinical insights which radiologists do not have access to today. One of Qlarity’s initial products, QuantX Advanced, is the first FDA-cleared, computer-aided breast cancer diagnosis software for radiology.

Skyline Biosciences

Skyline Biosciences is developing first in-kind oncology therapies to treat premalignant and malignant conditions with unmet medical need. Skyline’s mission is to alleviate potentially life-threatening conditions and to improve the quality of life for the patients it serves. For more information, please visit www.skylinebiosciences.com.

PORTFOLIO COMPANY PIPELINE

Paragon PipelineChart